文献速递心力衰竭与心肌病

达格列净在急性心力衰竭中的疗效与安全性

Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure.
PubMed 文献 · J Am Coll Cardiol · 2024-01-01

DICTATE-AHF 研究为多中心开放标签随机试验,240 例高容量性急性心衰患者在就诊 24 小时内随机接受达格列净 10 mg 每日一次或结构化常规治疗。主要终点利尿效率(累计体重变化/累计袢利尿剂剂量)两组无统计学差异(OR 0.65,95%CI 0.41-1.02,P=0.06);达格列净组袢利尿剂剂量更低、静脉利尿剂上调次数更少,且不增加安全性事件。

要点

  • 早期达格列净未显著改善基于体重的利尿效率,但可减少袢利尿剂用量。
  • 达格列净组 24 小时利钠和尿量增加,可能加速出院。
  • 早期启用达格列净未增加糖尿病、肾脏或心血管安全性事件。

核心结论

  • 急性心衰住院期间早期启用达格列净安全,并满足 GDMT 优化的一个组成部分。
  • 达格列净未显著减少基于体重的利尿效率,但有证据表明可增强利尿。

研究设计与样本

  • 多中心、开放标签随机研究,纳入 240 例高容量性急性心衰患者。
  • 患者在心衰就诊 24 小时内随机接受达格列净 10 mg 每日一次或结构化常规治疗,直至第 5 天或出院。
  • 常规治疗采用方案化利尿剂滴定;次要及安全性结局由盲法委员会裁定。
  • 主要终点为利尿效率,以累计体重变化/累计袢利尿剂剂量表示,采用调整基线体重的比例优势模型比较。

主要发现

  • 利尿效率两组无差异(OR 0.65;95%CI 0.41-1.02;P=0.06)。
  • 达格列净组袢利尿剂剂量更低(560 mg [Q1-Q3: 260-1,150 mg] vs 800 mg [Q1-Q3: 380-1,715 mg];P=0.006)。
  • 达格列净组静脉利尿剂上调次数更少(P≤0.05),达到与常规治疗相当的体重下降。
  • 达格列净与 24 小时利钠改善(P=0.03)和尿量增加(P=0.005)相关,并加速研究期间出院。
  • 早期达格列净未增加糖尿病、肾脏或心血管安全性事件。

临床怎么用

  • 急性心衰住院早期可考虑启用达格列净 10 mg 每日一次以优化 GDMT。
  • 达格列净可能有助于减少袢利尿剂用量和静脉利尿剂上调,但利尿效率未显著改善。

局限性

  • 开放标签设计。
  • 样本量 240 例,主要终点 P=0.06 未达统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The primary goals during acute heart failure (AHF) hospitalization are decongestion and guideline-directed medical therapy (GDMT) optimization. Unlike diuretics or other GDMT, early dapagliflozin initiation could achieve both AHF goals. OBJECTIVES: The authors aimed to assess the diuretic efficacy and safety of early dapagliflozin initiation in AHF. METHODS: In a multicenter, open-label study, 240 patients were randomized within 24 hours of hospital presentation for hypervolemic AHF to dapagliflozin 10 mg once daily or structured usual care with protocolized diuretic titration until day 5 or hospital discharge. The primary outcome, diuretic efficiency expressed as cumulative weight change per cumulative loop diuretic dose, was compared across treatment assignment using a proportional odds model adjusted for baseline weight. Secondary and safety outcomes were adjudicated by a blinded committee. RESULTS: For diuretic efficiency, there was no difference between dapagliflozin and usual care (OR: 0.65; 95% CI: 0.41-1.02; P = 0.06). Dapagliflozin was associated with reduced loop diuretic doses (560 mg [Q1-Q3: 260-1,150 mg] vs 800 mg [Q1-Q3: 380-1,715 mg]; P = 0.006) and fewer intravenous diuretic up-titrations (P ≤ 0.05) to achieve equivalent weight loss as usual care. Early dapagliflozin initiation did not increase diabetic, renal, or cardiovascular safety events. Dapagliflozin was associated with improved median 24-hour natriuresis (P = 0.03) and urine output (P = 0.005), expediting hospital discharge over the study period. CONCLUSIONS: Early dapagliflozin during AHF hospitalization is safe and fulfills a component of GDMT optimization. Dapagliflozin was not associated with a statistically significant reduction in weight-based diuretic efficiency but was associated with evidence for enhanced diuresis among patients with AHF. (Efficacy and Safety of Dapagliflozin in Acute Heart Failure [DICTATE-AHF]; NCT04298229).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Cox, Collins, Hernandez, et al. Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure. J Am Coll Cardiol. 2024. PMID: 38569758. doi:10.1016/j.jacc.2024.02.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。